Evidence map›Paper›PMID 41272414›Full record

SynthesisJournal of applied toxicology : JAT2026

Is Micronucleus Assay a Suitable Biomarker for Evaluating the Cancer Risk in Professionals Exposed to Antineoplastic Drugs? A Systematic Review.

Thiago Guedes Pinto, Lorrany da Silva Avanci, Gabriel Carvalhal de Aguiar, Daniel Vitor de Souza, Patricia Ramos Cury, Ana Claudia Muniz Renno, Daniel Araki Ribeiro

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Journal of applied toxicology : JAT, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Thiago Guedes PintoDepartment of Biosciences, Institute of Health and Society, Federal University of São Paulo, UNIFESP, Santos, SP, Brazil.
Lorrany da Silva AvanciDepartment of Biosciences, Institute of Health and Society, Federal University of São Paulo, UNIFESP, Santos, SP, Brazil.ORCID 0009-0005-2386-2126
Gabriel Carvalhal de AguiarDepartment of Biosciences, Institute of Health and Society, Federal University of São Paulo, UNIFESP, Santos, SP, Brazil.
Daniel Vitor de SouzaDepartment of Biosciences, Institute of Health and Society, Federal University of São Paulo, UNIFESP, Santos, SP, Brazil.ORCID 0000-0002-0999-5847
Patricia Ramos CuryDepartment of Periodontics, School of Dentistry, Federal University of Bahia, Salvador, BA, Brazil.ORCID 0000-0001-8907-0483
Ana Claudia Muniz RennoDepartment of Biosciences, Institute of Health and Society, Federal University of São Paulo, UNIFESP, Santos, SP, Brazil.
Daniel Araki RibeiroDepartment of Biosciences, Institute of Health and Society, Federal University of São Paulo, UNIFESP, Santos, SP, Brazil.ORCID 0000-0001-5057-4983

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 001Coordenação de Aperfeiçoamento de Pessoal de Nível Superior 001
6 · The paper itself

Abstract

The widespread use of antineoplastic drugs in cancer treatment has led to significant concerns regarding the potential health risks posed to healthcare professionals involved in the preparation, administration, and handling of these chemical compounds, including genotoxicity. This systematic review investigates the genotoxicity of various anticancer drugs through the micronucleus assay in mammalian cells through a comprehensive analysis of studies retrieved from PubMed, SCOPUS, and Web of Science. A systematic search conducted in May 2025 identified 28 relevant studies, all of which employed the micronucleus assay. The results indicated that 23 of the reviewed studies observed genotoxic effects linked to several drugs. As for the quality assessment, all studies (but one) were categorized as either strong or moderate; therefore, we consider our findings to be reliable. These findings raise significant concerns regarding the potential health risks associated with oncologic drugs, warranting further investigation and regulatory oversight to ensure professionals' safety. Finally, such findings are very important for clarifying the role of the micronucleus assay as a putative biomarker for evaluating the cancer risk due to anticancer drug exposure in humans.

Indexed as

Antineoplastic AgentsHealth PersonnelNeoplasmsOccupational ExposureAnimalsBiomarkersHumansMicronucleus TestsRisk AssessmentAntineoplastic AgentsBiomarkersanticancer drugsgenotoxicitymammalian cellsmicronucleus assay

Identifiers

PMID41272414
PMCPMC12861600

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.